Images List Premium Download Classic

Immunotherapy

Immunotherapy-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Adoptive immunotherapy for treating cancer
UniversitÉ De Lausanne
December 07, 2017 - N°20170349880

The present invention provides methods for producing and/or expanding tumor-infiltrating lymphocytes (tils) that can be used in adoptive immunotherapy in cancer treatment.
Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer ...
Immatics Biotechnologies Gmbh
November 30, 2017 - N°20170342125

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Immunotherapy against erbb-3 receptor
Takis S.r.l.
November 30, 2017 - N°20170342123

The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid dna and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the erbb-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ...
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of superantigens for improving mucosal allergen specific immunotherapy in human beings
Swecure As
November 23, 2017 - N°20170333551

Use of a superantigen in mucosal allergen specific immune therapy (asit) in a human being to enhance the effect thereof. In order to enhance the effect of the mucosal asit, the superantigen is mucosally administered before, or with, the allergen to the human being.
Size tunable microbial mimetics for immunotherapy of cancer
Swecure As
November 23, 2017 - N°20170333542

The mm exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The mm constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo.
Target peptides for immunotherapy and diagnostics
The University Of Birmingham
November 23, 2017 - N°20170333541

A set of target peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e. G., cancer, (b) to function as immunotherapeutics in adoptive t cell therapy or as a vaccine, (c) facilitate antibody recognition ...
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Immunotherapy against melanoma and other cancers
Immatics Biotechnologies Gmbh
November 16, 2017 - N°20170326216

A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in ...
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other ...
Immatics Biotechnologies Gmbh
November 16, 2017 - N°20170326215

A method of treating a patient who has liver cancer (hcc), breast cancer (brca), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that ...
Compositions and methods for inhibition of lineage specific antigens
The Trustees Of Columbia University In The
November 16, 2017 - N°20170326179

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.
Nlrc5 as a biomarker for cancer patients and a target for cancer therapy
The Texas A&m University System
November 09, 2017 - N°20170321285

The invention pertains to biomarkers for identifying a cancer that is likely or not likely to evade the immune system of a subject, thus, is likely or not likely to show better prognosis (prognostic biomarker) and/or better responses to cancer therapies (predictive biomarker). The invention provides a method of identifying a subject as having a cancer that is likely ...
Immunotherapy against several tumors, such as lung cancer, including nsclc
Immatics Biotechnologies Gmbh
November 09, 2017 - N°20170320913

A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a ...
Immunotherapy against several tumors, such as lung cancer, including nsclc
Immatics Biotechnologies Gmbh
November 09, 2017 - N°20170319675

A method of treating a patient who has non-small cell lung carcinoma (nsclc), lung cancer, gastric cancer, and/or glioblastoma includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
November 02, 2017 - N°20170313760

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary ...
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
Immatics Biotechnologies Gmbh
November 02, 2017 - N°20170312350

The present description relates to t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as igf2bp3-001 have ...
Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
Immatics Biotechnologies Gmbh
November 02, 2017 - N°20170312336

A method of treating a patient who has gastric cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, ...
Mirna for treating cancer and for use with adoptive immunotherapies
Immatics Biotechnologies Gmbh
November 02, 2017 - N°20170312304

In some aspects, mirna for the treatment of cancer are provided. In some embodiments, a mirna (e. G., mir-124, mir-142, and/or mir-138) may be used to promote or enhance immune destruction of a cancer, or reduce the immune suppression of the cancer, in a subject. In other aspects, the mirna may be used in, or in combination with, an ...
Immunogenic modulation by endocrine deprivation therapy improves sensitivity of tumor cells to immune mediated lysis
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv
October 26, 2017 - N°20170306042

The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e. G., enzalutamide, abiraterone, and tamoxifen) and immunotherapy.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
October 26, 2017 - N°20170305993

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
October 26, 2017 - N°20170305992

A method of treating a patient who has hepatocellular carcinoma (hcc), colorectal carcinoma (crc), glioblastoma (gb), gastric cancer (gc), esophageal cancer, nsclc, pancreatic cancer (pc), renal cell carcinoma (rcc), benign prostate hyperplasia (bph), prostate cancer (pca), ovarian cancer (oc), melanoma, breast cancer (brca), cll, merkel cell carcinoma (mcc), sclc, non-hodgkin lymphoma (nhl), aml, gallbladder cancer and cholangiocarcinoma (gbc, ccc), urinary ...
Immunotherapy against melanoma and other cancers
Immatics Biotechnologies Gmbh
October 26, 2017 - N°20170305991

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other ...
Immatics Biotechnologies Gmbh
October 26, 2017 - N°20170305982

A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated t cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated t cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, ...
Loading